• Focus on high value R&D underpinned by Arestat™ technology and Company expertise positions Arecor for significant future growth and success• Significant advancements in diabetes portfolio with positive progress towards strategic partnership for AT278• Potential to unlock significant value through innovation in the oral delivery of peptides• Growing revenue stream from AT220 global royalties• Expansion of partnership portfolio and licensing of Arestat™-enhanced products•…
Armed with a potent membrane protein production arsenal, Creative Biolabs stands by to lend a helping hand to researchers across the world so as to avoid the "doom loop" that has haunted membrane protein research for decades.Step aside AI and CRISPR—there's a new darling in biotech—membrane proteins, the cell gatekeepers behind 60% of all drug targets, are getting their time in the spotlight as breakthroughs in structural biology and drug design enter the mix and stimulate a frenzy of innovations. Creative Biolabs provides satisfactory membrane protein products and relatively flexible options…
Leading global drug development consultancy Boyds has strengthened its team with the appointment of senior regulatory affairs professional Kelsey Lenoch.
Kelsey joins Boyds as Associate Director, Regulatory Affairs in the US, bringing with her 15 years of experience in clinical research and drug development.
Previously, Kelsey was Senior Manager, Regulatory Affairs at Usona Institute, a non-profit medical research organization in Madison, Wisconsin, USA, working across both regulatory strategy and CMC development, supporting the clinical development of multiple psychedelic drugs. Prior to…
Membrane proteins synthesized and purified within 48 hours.
Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized
Cambridge, UK, and Boston MA, USA, 14 April 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free…
Creative Biolabs stands out in the race as brain diseases fuel a surge in demand for NHP biospecimens—cerebrospinal fluid (CSF)—functioning as the gold standard for validating next-gen brain therapies.A landmark study about gene therapy recently reported in Nature Biotechnology indicating 27% cognitive improvement in Alzheimer's mice using circular RNA has set labs scrambling for high-quality NHP samples that are firmly determined as the gold standard for bridging preclinical breakthroughs to human trials."Monkey CSF is more than just liquid, but a roadmap to the brain," says a neurology…
Working with leading research institutions, Amsbio has established itself as a premier supplier of high quality Heparan Sulfate (HS) monoclonal antibodies driving breakthroughs in Glycobiology research.
Heparan Sulfate (HS) is widely distributed on cell surfaces and basement membranes in mammals. It participates in important biological processes due to displaying specific interactions with many biologically active proteins. However, due to its non-immunogenic nature, developing effective antibodies against HS has long been a challenge.
Amsbio has overcome these…
Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Melanie Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca, as a Non-Executive Director.
Melanie is an established preclinical drug discovery leader with a track record of developing and inspiring diverse, high performing teams, to deliver innovative science and technology. Melanie…
Cambridge, UK, 10 April 2025: Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalised healthcare testing services. The acquisition bolsters the Company’s clinical diagnostics portfolio by leveraging the expertise of the CCL team and new state-of-the-art clinical lab facilities at Vision Park in Cambridge, providing streamlined testing services for both preclinical and clinical research.
CCL…
London, April 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.Dr. Mark Velleca is currently the CEO and Board Chair of Black Diamond Therapeutics (BDTX) and also serves as Board Chair of Myeloid…
Howard Group strengthens its South Cambridge science and healthcare ecosystem with latest signing
Cambridge, 8thApril 2025: Leading regional property investor and developer Howard Group, is pleased to welcome Granta Medical Practices (GMP) to Langford Arch, having agreed a five-year lease for 5,767 sq ft of office space with the primary care provider.
GMP is the latest healthcare business to join Langford Arch, which is adjacent to Howard Group’s flagship science and technology hub, Unity Campus.
GMP is a Primary Care Network providing NHS primary care services to 57,000…